News summary
[Microchip Bio: Application for Phase III clinical trial of Sidabenamide for colorectal cancer treatment accepted] Securities Times e Company News, Microchip Bio (688321) announced on the evening of May 12 that the company recently received a drug review from the State Food and Drug Administration Issued by the CenterfreeonlinepokergamesClinical trial for registration of domestically produced drugsfreeonlinepokergames.freeonlinepokergames..
Newsletter text
[Microchip Bio: Application for Phase III clinical trial of Sidabenamide for colorectal cancer treatment accepted] Securities Times e Company News, Microchip Bio (688321) announced on the evening of May 12 that the company recently received a drug review from the State Food and Drug Administration Issued by the CenterfreeonlinepokergamesThe "Acceptance Notice" for the registration clinical trial of domestically produced drugs, a randomized, open-label, controlled, multi-center, phase III clinical trial of cidabenamide combined with sintilumab and bevacizumab for the treatment of advanced microsatellite stability or complete mismatch repair (MSS/pMMR) colorectal cancer that failed ≥2 lines of standard treatment was accepted by the Center for Drug Evaluation of the State Food and Drug Administration.
